<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">The rapid development of ARDS in patients diagnosed with COVID-19 may not be primarily due to SARS-CoV-2 per se but the cytokine storm [
 <xref ref-type="bibr" rid="CR58">58</xref>]. Interleukin (IL)-6 is one of the most important pro-inflammatory cytokines [
 <xref ref-type="bibr" rid="CR58">58</xref>]. Hence, specific blockade of the IL-6-regulated signaling pathways represents a promising approach to attenuate inflammation-associated damage [
 <xref ref-type="bibr" rid="CR59">59</xref>]. Tocilizumab is an antihuman interleukin 6 (IL-6) receptor monoclonal antibody approved for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis [
 <xref ref-type="bibr" rid="CR60">60</xref>, 
 <xref ref-type="bibr" rid="CR61">61</xref>]. In a recently published study of 15 patients with COVID-19, tocilizumab combined with methylprednisolone ameliorated increased CRP and IL-6, but the result was insufficient to support its therapeutic effects [
 <xref ref-type="bibr" rid="CR62">62</xref>]. Upon the recently launched randomized, double-blind, placebo-controlled phase III clinical trial called COVACTA, the safety and efficacy of intravenous tocilizumab in hospitalized adult patients with severe COVID-19 pneumonia will be compared with placebo in addition to the standard of care [
 <xref ref-type="bibr" rid="CR63">63</xref>].
</p>
